Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Article in English | MEDLINE | ID: mdl-33819321

ABSTRACT

This paper reports on a study undertaken to ascertain the efficacy of the erbium:YAG laser (EYL) for peri-implantitis treatment. A total of 12 patients with bone loss resulting from peri-implantitis were involved in this study. The treatment protocol consisted of using the EYL for implant surface debridement and deproteinized bovine bone mineral (DBBM) for bone grafting. The following parameters were analyzed: probing pocket depth (PPD), clinical attachment level (CAL), bleeding on probing (BOP), bone levels (BLs), and the lipopolysaccharide levels before and after debridement with the EYL. This study found a statistically significant improvement in PPD, CAL, BOP, and BL at 3 and 12 months postoperative. Furthermore, a statistically significant decrease in implant-surface LPS levels was observed following debridement with the EYL. These findings show that using the EYL for debridement in peri-implantitis cases is effective in decreasing LPS levels. Moreover, after partial reconstruction with DBBM grafting, BLs were restored for at least 12 months. It was shown in one case that BLs had remained stable over 6 years, which also attests to the efficacy of this treatment. The combined use of EYL and DBBM could be effective for regenerative surgical peri-implantitis treatment.


Subject(s)
Dental Implants , Lasers, Solid-State , Peri-Implantitis , Animals , Biomarkers , Cattle , Erbium , Humans , Lasers, Solid-State/therapeutic use , Peri-Implantitis/surgery
2.
J Clin Exp Dent ; 10(10): e970-e978, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30386502

ABSTRACT

BACKGROUND: The effectiveness of an erbium-doped: yttrium, aluminum and garnet (Er: YAG) laser (EYL) for the treatment of peri-implant disease (PID) remains unclear. The aim of this study was to compare non-surgical EYL therapy for PID with locally delivered minocycline hydrochloride (MC) ointment therapy by evaluating clinical, microbiological, and biochemical markers. MATERIAL AND METHODS: Thirty-seven patients with PID were randomly assigned to either the EYL group (n = 18) or the MC group (n = 19). The clinical, microbiological, and biochemical markers at baseline and at 1 and 3 months after treatment were compared between the two groups. Subgingival plaque and peri-implant crevicular fluid (PICF) were collected from the diseased pockets. RESULTS: In the EYL group, probing pocket depth (PPD) was significantly decreased after treatment when compared with baseline. On the other hand, in the MC group, there was no significant decrease in PPD after treatment. Specific bacteria associated with PID were not determined. The counts of both Gram-positive and -negative species did not significantly decrease in the EYL group at 3 months after treatment. In the MC group, the counts of almost all bacterial species were significantly decreased after treatment. Biochemical marker analysis of PICF revealed significantly lower levels of metalloproteinase (MMP)-9 in the EYL group, as compared with the MC group at 3 months after treatment (p= 0.009). CONCLUSIONS: Non-surgical therapy with an EYL for PID was clinically effective, with decreased MMP-9 levels in PICF, which may lead to reduced peri-implant tissue destruction. Key words:Er: YAG laser; peri-implant disease; biomarker; peri-implant crevicular fluid.

3.
J Oral Sci ; 59(1): 1-11, 2017 Mar 31.
Article in English | MEDLINE | ID: mdl-27725369

ABSTRACT

We investigated the prevalences and risk factors for peri-implant diseases in Japanese adult dental patients attending a follow-up visit at dental hospitals or clinics as part of their maintenance program. This cross-sectional multicenter study enrolled patients with dental implants who attended regular check-ups as part of a periodontal maintenance program during the period from October 2012 through September 2013. Patients with implants with at least 3 years of loading time were included in the study. The condition of peri-implant tissue was examined and classified into the following categories: healthy, peri-implant mucositis, and peri-implantitis. Patients were also evaluated for implant risk factors. A total of 267 patients (110 men, 157 women; mean age: 62.5 ± 10.7 years) were analyzed. The prevalence of patient-based peri-implant mucositis was 33.3% (n = 89), and the prevalence of peri-implantitis was 9.7% (n = 26). Poor oral hygiene and a history of periodontitis were strong risk factors for peri-implant disease. The present prevalences were lower than those previously reported. The quality of periodontal therapy before and after implant installation and patient compliance and motivation, as indicated by plaque control level, appear to be important in maintaining peri-implant tissue health.


Subject(s)
Peri-Implantitis/epidemiology , Adult , Aged , Aged, 80 and over , Cross-Sectional Studies , Female , Humans , Japan/epidemiology , Male , Middle Aged , Prevalence , Risk Factors , Young Adult
5.
J Biomater Appl ; 26(4): 435-49, 2011 Nov.
Article in English | MEDLINE | ID: mdl-20624844

ABSTRACT

Previous studies have demonstrated that carbonate apatite (CA) is superior to hydroxyapatite (HA) and ß-tricalciumphosphate (ß-TCP) with regard to osteoclastic resorption, but evidence on osteoclast and osteoblast response remains controversial. In the present study, the expression of bone related mRNA is examined on CA, HA, ß-TCP, and titanium plates. ICR mouse osteoblast cells are cocultured with ICR mouse bone marrow cells. Crude osteoclast-like cell-rich suspensions are then seeded onto plates and cultured for 48 h. Total RNA is extracted and mRNA expression is examined by real-time RT-PCR. Amounts of vacuolar-type ATPase, cathepsin K, and TRAP mRNA are significantly greater on CA than on the other plates. The amount of osteoprotegerin mRNA is significantly greater on CA than on the other plates. RANKL mRNA expression, which is generally regarded as an osteoblast maker, varies with material, but shows no significant differences between CA and the other plates. The formation and activity of osteoclasts is greater with CA than with the other plates. Thus, CA is superior to ß-TCP as a bioresorbable bone substitute for tissue engineering.


Subject(s)
Apatites , Biocompatible Materials , Osteoblasts/metabolism , Osteoclasts/metabolism , Acid Phosphatase/genetics , Animals , Bone Substitutes , Calcium Phosphates , Cathepsin K/genetics , Cell Culture Techniques , Collagen Type I/genetics , Durapatite , Gene Expression , Isoenzymes/genetics , Materials Testing , Mice , Osteoblasts/cytology , Osteoclasts/cytology , Osteoprotegerin/genetics , RANK Ligand/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , Tartrate-Resistant Acid Phosphatase , Tissue Engineering , Vacuolar Proton-Translocating ATPases/genetics
6.
PLoS One ; 3(7): e2611, 2008 Jul 02.
Article in English | MEDLINE | ID: mdl-18596969

ABSTRACT

BACKGROUND: The options for medical use of signaling molecules as stimulators of tissue regeneration are currently limited. Preclinical evidence suggests that fibroblast growth factor (FGF)-2 can promote periodontal regeneration. This study aimed to clarify the activity of FGF-2 in stimulating regeneration of periodontal tissue lost by periodontitis and to evaluate the safety of such stimulation. METHODOLOGY/PRINCIPAL FINDINGS: We used recombinant human FGF-2 with 3% hydroxypropylcellulose (HPC) as vehicle and conducted a randomized double-blinded controlled trial involving 13 facilities. Subjects comprised 74 patients displaying a 2- or 3-walled vertical bone defect as measured > or = 3 mm apical to the bone crest. Patients were randomly assigned to 4 groups: Group P, given HPC with no FGF-2; Group L, given HPC containing 0.03% FGF-2; Group M, given HPC containing 0.1% FGF-2; and Group H, given HPC containing 0.3% FGF-2. Each patient underwent flap operation during which we administered 200 microL of the appropriate investigational drug to the bone defect. Before and for 36 weeks following administration, patients underwent periodontal tissue inspections and standardized radiography of the region under investigation. As a result, a significant difference (p = 0.021) in rate of increase in alveolar bone height was identified between Group P (23.92%) and Group H (58.62%) at 36 weeks. The linear increase in alveolar bone height at 36 weeks in Group P and H was 0.95 mm and 1.85 mm, respectively (p = 0.132). No serious adverse events attributable to the investigational drug were identified. CONCLUSIONS: Although no statistically significant differences were noted for gains in clinical attachment level and alveolar bone gain for FGF-2 groups versus Group P, the significant difference in rate of increase in alveolar bone height (p = 0.021) between Groups P and H at 36 weeks suggests that some efficacy could be expected from FGF-2 in stimulating regeneration of periodontal tissue in patients with periodontitis. TRIAL REGISTRATION: ClinicalTrials.gov NCT00514657.


Subject(s)
Fibroblast Growth Factor 2/therapeutic use , Guided Tissue Regeneration, Periodontal/methods , Periodontal Diseases/drug therapy , Double-Blind Method , Follow-Up Studies , Humans , Recombinant Proteins/therapeutic use , Treatment Outcome
7.
Spec Care Dentist ; 27(4): 149-53, 2007.
Article in English | MEDLINE | ID: mdl-17972446

ABSTRACT

To evaluate the effects of dementia on denture-handling ability, we measured the amount of time that elderly subjects spent inserting and removing dentures. Elderly subjects with dementia tended to take more time inserting and removing dentures than those who were not demented. Only elderly patients who were severely demented needed significantly more time removing partial dentures than they did removing complete dentures. There was no significant difference between the time spent inserting dentures and removing dentures. The greater amount of time required to insert or remove dentures for subjects with dementia was due to disorientation. The results indicate that elderly people with mild to moderate dementia are able to insert and remove their dentures without help.


Subject(s)
Dementia , Dental Care for Aged , Dentures , Psychomotor Performance , Aged , Female , Hand Strength , Humans , Male , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...